Efficacy of contrast-enhanced endoscopic ultrasonography for diagnosing pancreatic tumor

Efficacy of contrast-enhanced endoscopic ultrasonography for diagnosing pancreatic tumor - Efficacy of contrast-enhanced endoscopic ultrasonography for diagnosing pancreatic tumor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025192

Enrollment

100

Registered

2016-12-08

Start date

2016-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic tumor

Interventions

Contrast-enhanced endoscopic ultrasonography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who indicate pancreatic tumor tract by imaging study Patient who intend to endoscopic ultrasound-guided fine-needle aspiration for pancreatic tumor Written informed consent ECOG performance status = 0-2

Exclusion criteria

Exclusion criteria: Inapropriate to perform endoscopic ultrasonography Blood coagulation disorder(PT-INR>1.5)or fewer platelets(<50,000mm3) Patient who take anticoagulant or antiplatelet drug cannot stop these drugs Allergy to iodine or eggs Chances of pregnancy Failure of other organs(ASA:Grade 3,4) Inability to obtain informed consent

Design outcomes

Primary

Measure	Time frame
Diagnostic ability for benign and malignant lymph nodes by using qualitative evaluation of contrast-enhanced endoscopic ultrasonography	—

Secondary

Measure	Time frame
To assess the usefulness of quantitative evaluation by using TIC analysis	—

Countries

Japan

Contacts

Public ContactTakuji Iwashita

Gifu University Faculty of Medicine Department of gastroenterology

takuji@w7.dion.ne.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026